Combined analysis of circulating β-endorphin with gene polymorphisms in OPRM1, CACNAD2 and ABCB1 reveals correlation with pain, opioid sensitivity and opioid-related side effects

Molecular Brain

Volumn 6, Issue 1, 2013, Pages

  Rhodin, Annica ^a,d   Grönbladh, Alfhild ^b   Ginya, Harumi ^c   Nilsson, Kent W ^d   Rosenblad, Andreas ^d   Zhou, Qin ^b   Enlund, Mats ^a,d   Hallberg, Mathias ^b   Gordh, Torsten ^a   Nyberg, Fred ^b  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c Precision System Science Co Ltd   (Japan)

^d CENTRAL HOSPITAL   (Sweden)

Author keywords

endorphin; ATP binding cassette B1 (ABCB1); Calcium channel subunit 2 (CACNA2D2); Chronic pain; Gene polymorphism; mu 1 opioid peptide receptor (OPRM1); Opioid sensitivity

Indexed keywords

ASPARAGINE; BETA ENDORPHIN; CALCIUM CHANNEL; CALCIUM CHANNEL SUBUNIT 2; MU 1 OPIATE PEPTIDE RECEPTOR; MU OPIATE RECEPTOR; MULTIDRUG RESISTANCE PROTEIN 1; OPIATE; REMIFENTANIL; UNCLASSIFIED DRUG;

ADULT; AGED; AMINO ACID SEQUENCE; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; INCIDENCE; LOW BACK PAIN; MAJOR CLINICAL STUDY; MALE; NOCICEPTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; SEDATION; SEX DIFFERENCE; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SPINE FUSION; STRESS; SWEATING; TENSION;

ADULT; AGED; ANALGESICS, OPIOID; BETA-ENDORPHIN; CALCIUM CHANNELS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; P-GLYCOPROTEIN; PAIN; POLYMORPHISM, SINGLE NUCLEOTIDE; QUALITY OF LIFE; RECEPTORS, OPIOID, MU;

EID: 84873700767     PISSN: None     EISSN: 17566606     Source Type: Journal    
DOI: 10.1186/1756-6606-6-8     Document Type: Article

References (66)

1. Opioids for chronic noncancer pain: a new Canadian practice guideline. Furlan AD, Reardon R, Weppler C, CMAJ 2010 182 923 930 20439443
2. Pain sensitivity and opioid analgesia: a pharmacogenomic twin study. Angst MS, Phillips NG, Drover DR, Tingle M, Ray A, Swan GE, Lazzeroni LC, Clark JD, Pain 2012 153 1397 1409 10.1016/j.pain.2012.02.022 22444188
3. How individual sensitivity to opiates can be predicted by gene analyses. Ikeda K, Ide S, Han W, Hayashida M, Uhl GR, Sora I, Trends Pharmacol Sci 2005 26 311 317 10.1016/j.tips.2005.04.001 15925706 (Pubitemid 40733524)
4. Pharmacogenetics of opioids. Somogyi AA, Barratt DT, Coller JK, Clin Pharmacol Ther 2007 81 429 444 10.1038/sj.clpt.6100095 17339873 (Pubitemid 46364493)
5. Genomic variations and transcriptional regulation of the human mu-opioid receptor gene. Bayerer B, Stamer U, Hoeft A, Stuber F, Eur J Pain 2007 11 421 427 10.1016/j.ejpain.2006.06.004 16843022 (Pubitemid 46366768)
6. Three major haplotypes of the beta2 adrenergic receptor define psychological profile, blood pressure, and the risk for development of a common musculoskeletal pain disorder. Diatchenko L, Anderson AD, Slade GD, Fillingim RB, Shabalina SA, Higgins TJ, Sama S, Belfer I, Goldman D, Max MB, Am J Med Genet B Neuropsychiatr Genet 2006 141B 449 462 10.1002/ajmg.b.30324 16741943 (Pubitemid 44024438)
7. Identifying pain genes: bottom-up and top-down approaches. Mogil JS, McCarson KE, J Pain 2000 1 66 80 10.1054/jpai.2000.9821 14622845
8. Candidate gene studies of human pain mechanisms: methods for optimizing choice of polymorphisms and sample size. Belfer I, Wu T, Kingman A, Krishnaraju RK, Goldman D, Max MB, Anesthesiology 2004 100 1562 1572 10.1097/00000542- 200406000-00032 15166579 (Pubitemid 38684137)
9. Pain and genetics. Fernandez Robles CR, Degnan M, Candiotti KA, Curr Opin Anaesthesiol 2012 25 444 449 10.1097/ACO.0b013e3283556228 22732422
10. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Bond C, LaForge KS, Tian M, Melia D, Zhang S, Borg L, Gong J, Schluger J, Strong JA, Leal SM, Proc Natl Acad Sci USA 1998 95 9608 9613 10.1073/pnas.95.16.9608 9689128 (Pubitemid 28506279)
11. A single nucleotide polymorphic mutation in the human mu-opioid receptor severely impairs receptor signaling. Befort K, Filliol D, Decaillot FM, Gaveriaux-Ruff C, Hoehe MR, Kieffer BL, J Biol Chem 2001 276 3130 3137 10.1074/jbc.M006352200 11067846
12. A118G single nucleotide polymorphism of human mu-opioid receptor gene influences pain perception and patient-controlled intravenous morphine consumption after intrathecal morphine for postcesarean analgesia. Sia AT, Lim Y, Lim EC, Goh RW, Law HY, Landau R, Teo YY, Tan EC, Anesthesiology 2008 109 520 526 10.1097/ALN.0b013e318182af21 18719451
13. ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals. Coller JK, Barratt DT, Dahlen K, Loennechen MH, Somogyi AA, Clin Pharmacol Ther 2006 80 682 690 10.1016/j.clpt.2006.09.011 17178268 (Pubitemid 44920224)
14. Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Campa D, Gioia A, Tomei A, Poli P, Barale R, Clin Pharmacol Ther 2008 83 559 566 10.1038/sj.clpt.6100385 17898703 (Pubitemid 351417058)
15. Genetic variability of the mu-opioid receptor influences intrathecal fentanyl analgesia requirements in laboring women. Landau R, Kern C, Columb MO, Smiley RM, Blouin JL, Pain 2008 139 5 14 10.1016/j.pain.2008.02.023 18403122
16. Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Reyes-Gibby CC, Shete S, Rakvag T, Bhat SV, Skorpen F, Bruera E, Kaasa S, Klepstad P, Pain 2007 130 25 30 10.1016/j.pain.2006.10.023 17156920 (Pubitemid 46850782)
17. The 118 A > G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Klepstad P, Rakvag TT, Kaasa S, Holthe M, Dale O, Borchgrevink PC, Baar C, Vikan T, Krokan HE, Skorpen F, Acta Anaesthesiol Scand 2004 48 1232 1239 10.1111/j.1399-6576.2004.00517.x 15504181 (Pubitemid 39490855)
18. The A118G single nucleotide polymorphism of the mu-opioid receptor gene (OPRM1) is associated with pressure pain sensitivity in humans. Fillingim RB, Kaplan L, Staud R, Ness TJ, Glover TL, Campbell CM, Mogil JS, Wallace MR, J Pain 2005 6 159 167 10.1016/j.jpain.2004.11.008 15772909 (Pubitemid 40365019)
19. Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein. Wandel C, Kim R, Wood M, Wood A, Anesthesiology 2002 96 913 920 10.1097/00000542-200204000-00019 11964599 (Pubitemid 34266685)
20. Genuine functions of P-glycoprotein (ABCB1). Mizutani T, Masuda M, Nakai E, Furumiya K, Togawa H, Nakamura Y, Kawai Y, Nakahira K, Shinkai S, Takahashi K, Curr Drug Metab 2008 9 167 174 10.2174/138920008783571756 18288958 (Pubitemid 351461005)
21. Genetic polymorphisms of the human MDR1 drug transporter. Schwab M, Eichelbaum M, Fromm MF, Annu Rev Pharmacol Toxicol 2003 43 285 307 10.1146/annurev.pharmtox.43.100901.140233 12359865 (Pubitemid 37372643)
22. Functional properties of a new voltage-dependent calcium channel alpha(2)delta auxiliary subunit gene (CACNA2D2). Gao B, Sekido Y, Maximov A, Saad M, Forgacs E, Latif F, Wei MH, Lerman M, Lee JH, Perez-Reyes E, J Biol Chem 2000 275 12237 12242 10.1074/jbc.275.16.12237 10766861 (Pubitemid 30237803)
23. G protein modulation of CaV2 voltage-gated calcium channels. Currie KP, Channels (Austin) 2010 4 497 509
24. Voltage-gated calcium channels and pain. Cao YQ, Pain 2006 126 5 9 10.1016/j.pain.2006.10.019 17084979 (Pubitemid 44751981)
25. Differential effect of gabapentin on neuronal and muscle calcium currents. Alden KJ, Garcia J, J Pharmacol Exp Ther 2001 297 727 735 11303064 (Pubitemid 32378006)
26. A G-to-A single nucleotide polymorphism in the human alpha 2 delta 2 calcium channel subunit gene that maps at chromosome 3p21.3. Angeloni D, Wei MH, Duh FM, Johnson BE, Lerman MI, Mol Cell Probes 2000 14 53 54 10.1006/mcpr.1999.0277 10722793 (Pubitemid 30168907)
27. Peripheral beta-endorphin and pain modulation. Hartwig AC, Anesth Prog 1991 38 75 78 1814247
28. Beta-endorphin response to exercise an update. Goldfarb AH, Jamurtas AZ, Sports Med 1997 24 8 16 10.2165/00007256-199724010-00002 9257407
29. Evidence that beta-endorphin is an agonist at bovine pineal delta-opioid receptors. Aloyo VJ, Pazdalski PS, Eur J Pharmacol 1995 288 295 301 10.1016/0922-4106(95)90041-1 7774673
30. Proopiomelanocortin (POMC) mRNA expression: distribution and region-specific down-regulation by chronic morphine in female guinea pig hypothalamus. Fang Y, Kelly MJ, Ronnekleiv OK, Brain Res Mol Brain Res 1998 55 1 8 10.1016/S0169-328X(97)00348-3 9645954 (Pubitemid 28236585)
31. Performing the exact test of Hardy-Weinberg proportion for multiple alleles. Guo SW, Thompson EA, Biometrics 1992 48 361 372 10.2307/2532296 1637966
32. Trends in long-term opioid therapy for chronic non-cancer pain. Boudreau D, Von Korff M, Rutter CM, Saunders K, Ray GT, Sullivan MD, Campbell CI, Merrill JO, Silverberg MJ, Banta-Green C, Weisner C, Pharmacoepidemiol Drug Saf 2009 18 1166 1175 10.1002/pds.1833 19718704
33. Increasing use of opioids from 2004 to 2007-pharmacoepidemiological data from a complete national prescription database in Norway. Fredheim OM, Skurtveit S, Breivik H, Borchgrevink PC, Eur J Pain 2010 14 289 294 10.1016/j.ejpain. 2009.05.006 19505834
34. Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. Arner S, Meyerson BA, Pain 1988 33 11 23 10.1016/0304-3959(88)90198-4 2454440
35. Pain responsiveness to opioids: central versus peripheral neuropathic pain. Smith HS, Meek PD, J Opioid Manag 2011 7 391 400 10.4113/jom.2011.1153 22165038
36. Allelic variation in human gene expression. Yan H, Yuan W, Velculescu VE, Vogelstein B, Kinzler KW, Science 2002 297 1143 10.1126/science.1072545 12183620 (Pubitemid 36193340)
37. Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. Zhang Y, Wang D, Johnson AD, Papp AC, Sadee W, J Biol Chem 2005 280 32618 32624 10.1074/jbc.M504942200 16046395 (Pubitemid 41368304)
38. Plasmatic beta-endorphin levels and thalamic surgery for pain. Lopez JA, Peran F, Altuzarra A, Garrido F, Arjona V, Neurol Res 1985 7 35 38 2860587 (Pubitemid 15101742)
39. Continuous subcutaneous administration of high-dose salmon calcitonin in bone metastasis: pain control and beta-endorphin plasma levels. Mystakidou K, Befon S, Hondros K, Kouskouni E, Vlahos L, J Pain Symptom Manage 1999 18 323 330 10.1016/S0885-3924(99)00081-0 10584455 (Pubitemid 29528467)
40. Primary headaches: reduced circulating beta-lipotropin and beta-endorphin levels with impaired reactivity to acupuncture. Facchinetti F, Nappi G, Savoldi F, Genazzani AR, Cephalalgia 1981 1 195 201 10.1046/j.1468-2982.1981.0104195.x 6290071 (Pubitemid 12191433)
41. Relationship between pain severity and serum beta-endorphin levels in postoperative patients. Leonard TM, Klem SA, Asher MA, Rapoff MA, Leff RD, Pharmacotherapy 1993 13 378 381 8361864 (Pubitemid 23219370)
42. Plasma Beta-endorphin levels before and after relief of cancer pain. El-Sheikh N, Boswell MV, Pain Physician 2004 7 67 70 16868614 (Pubitemid 38195755)
43. A genetic association study of the functional A118G polymorphism of the human mu-opioid receptor gene in patients with acute and chronic pain. Janicki PK, Schuler G, Francis D, Bohr A, Gordin V, Jarzembowski T, Ruiz-Velasco V, Mets B, Anesth Analg 2006 103 1011 1017 10.1213/01.ane.0000231634.20341.88 17000822 (Pubitemid 44576714)
44. Association between human opioid receptor genes polymorphisms and pressure pain sensitivity in females*. Huang CJ, Liu HF, Su NY, Hsu YW, Yang CH, Chen CC, Tsai PS, Anaesthesia 2008 63 1288 1295 10.1111/j.1365-2044. 2008.05760.x 19032295
45. Human opioid receptor A118G polymorphism affects intravenous patient-controlled analgesia morphine consumption after total abdominal hysterectomy. Chou WY, Wang CH, Liu PH, Liu CC, Tseng CC, Jawan B, Anesthesiology 2006 105 334 337 10.1097/00000542-200608000-00016 16871067 (Pubitemid 44148178)
46. Association of mu-opioid receptor gene polymorphism (A118G) with variations in morphine consumption for analgesia after total knee arthroplasty. Chou WY, Yang LC, Lu HF, Ko JY, Wang CH, Lin SH, Lee TH, Concejero A, Hsu CJ, Acta Anaesthesiol Scand 2006 50 787 792 10.1111/j.1399-6576.2006.01058.x 16879459 (Pubitemid 44034227)
47. [Postoperative pain management following orthognathic surgery in consideration of individual differences - is the antinociceptive effect of fentanyl related to the genotype involving nucleotide at OPRM1?]. Fukuda K, Hayashida M, Ikeda K, Masui 2009 58 1102 1108 19764432
48. The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine. Lotsch J, Skarke C, Grosch S, Darimont J, Schmidt H, Geisslinger G, Pharmacogenetics 2002 12 3 9 10.1097/00008571-200201000-00002 11773859 (Pubitemid 34112237)
49. Does the A118G polymorphism at the mu-opioid receptor gene protect against morphine-6-glucuronide toxicity? Lotsch J, Zimmermann M, Darimont J, Marx C, Dudziak R, Skarke C, Geisslinger G, Anesthesiology 2002 97 814 819 10.1097/00000542-200210000-00011 12357145
50. Sequence variations in the mu-opioid receptor gene (OPRM1) associated with human addiction to heroin. Shi J, Hui L, Xu Y, Wang F, Huang W, Hu G, Hum Mutat 2002 19 459 460 11933204
51. Effect of the A118G polymorphism on binding affinity, potency and agonist-mediated endocytosis, desensitization, and resensitization of the human mu-opioid receptor. Beyer A, Koch T, Schroder H, Schulz S, Hollt V, J Neurochem 2004 89 553 560 10.1111/j.1471-4159.2004.02340.x 15086512 (Pubitemid 38534141)
52. The influence of ATP-binding cassette sub-family B member 1 (ABCB1) genetic polymorphisms on acute and chronic pain after intrathecal morphine for caesarean section: a prospective cohort study. Sia AT, Sng BL, Lim EC, Law H, Tan EC, Int J Obstet Anesth 2010 19 254 260 10.1016/j.ijoa.2010.03.001 20627697
53. Genetic variants of the P-glycoprotein gene Abcb1b modulate opioid-induced hyperalgesia, tolerance and dependence. Liang DY, Liao G, Lighthall GK, Peltz G, Clark DJ, Pharmacogenet Genomics 2006 16 825 835 10.1097/01.fpc.0000236321.94271.f8 17047491 (Pubitemid 44632297)
54. Environmental and genetic factors associated with morphine response in the postoperative period. Coulbault L, Beaussier M, Verstuyft C, Weickmans H, Dubert L, Tregouet D, Descot C, Parc Y, Lienhart A, Jaillon P, Becquemont L, Clin Pharmacol Ther 2006 79 316 324 10.1016/j.clpt.2006.01.007 16580900
55. Genetic polymorphisms in the ABCB1 gene and the effects of fentanyl in Koreans. Park HJ, Shinn HK, Ryu SH, Lee HS, Park CS, Kang JH, Clin Pharmacol Ther 2007 81 539 546 10.1038/sj.clpt.6100046 17192767 (Pubitemid 46452300)
56. Interindividual variability of methadone response: impact of genetic polymorphism. Li Y, Kantelip JP, Gerritsen-van Schieveen P, Davani S, Mol Diagn Ther 2008 12 109 124 18422375 (Pubitemid 351570866)
57. Increased (R)-methadone plasma concentrations by quetiapine in cytochrome P450s and ABCB1 genotyped patients. Uehlinger C, Crettol S, Chassot P, Brocard M, Koeb L, Brawand-Amey M, Eap CB, J Clin Psychopharmacol 2007 27 273 278 10.1097/JCP.0b013e3180592ad2 17502774 (Pubitemid 46763309)
58. Promoter polymorphisms and allelic imbalance in ABCB1 expression. Loeuillet C, Weale M, Deutsch S, Rotger M, Soranzo N, Wyniger J, Lettre G, Dupre Y, Thuillard D, Beckmann JS, Pharmacogenet Genomics 2007 17 951 959 10.1097/FPC.0b013e3282eff934 18075465 (Pubitemid 350293795)
59. Update on the genetics of migraine. Estevez M, Gardner KL, Hum Genet 2004 114 225 235 10.1007/s00439-003-1055-9 14624354 (Pubitemid 38208299)
60. A118G Mu Opioid Receptor polymorphism increases inhibitory effects on CaV2.2 channels. Lopez Soto EJ, Raingo J, Neurosci Lett 2012 523 190 194 10.1016/j.neulet.2012.06.074 22796651
61. Pain questionnaires in the analysis of long lasting (chronic) pain conditions. Wincent A, Liden Y, Arner S, Eur J Pain 2003 7 311 321 10.1016/S1090-3801(03)00044-2 12821401 (Pubitemid 36858229)
62. Health-related quality of life in the general Norwegian population assessed by the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire: the QLQ=C30 (+ 3). Hjermstad MJ, Fayers PM, Bjordal K, Kaasa S, J Clin Oncol 1998 16 1188 1196 9508207 (Pubitemid 28108757)
63. Patient-maintained remifentanil target-controlled infusion for the transition to early postoperative analgesia. Schraag S, Kenny GN, Mohl U, Georgieff M, Br J Anaesth 1998 81 365 368 10.1093/bja/81.3.365 9861121 (Pubitemid 28416614)
64. A comparison of pressure pain thresholds in different tissues and body regions. Long-term reliability of pressure algometry in healthy volunteers. Kosek E, Ekholm J, Nordemar R, Scand J Rehabil Med 1993 25 117 124 8248762 (Pubitemid 23303947)
65. Development of the Handy Bio-Strand and its application to genotyping of OPRM1 (A118G). Ginya H, Asahina J, Yoshida M, Segawa O, Asano T, Ikeda H, Hatano YM, Shishido M, Johansson BM, Zhou Q, Anal Biochem 2007 367 79 86 10.1016/j.ab.2007.04.052 17570330 (Pubitemid 46935609)
66. Concomitant increase in blood plasma levels of immunoreactive hemorphin-7 and beta-endorphin following long distance running. Glamsta EL, Morkrid L, Lantz I, Nyberg F, Regul Pept 1993 49 9 18 10.1016/0167-0115(93)90378-L 7904083